Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled time : 00:00 save search
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 1.28%
H: 5.68%
C: -0.32%
obesity momentum positive topline trial results phase 2
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
Published: 2023-11-16 (Crawled : 00:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.39%
H: 0.71%
C: 0.18%
trial china phase 2
Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-11-07 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 5.96%
H: 8.43%
C: 6.43%
ath434 system trial therapeutics phase 2
Port Arthur LNG Phase 2 Project Receives Federal Energy Regulatory Commission Authorization
Published: 2023-09-21 (Crawled : 00:00) - prnewswire.com
SRE | News | $70.08 2.4% -0.71% 3.1M
|
Utilities
|
| O: -0.44%
H: 0.99%
C: 0.25%
energy authorization phase 2
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Published: 2023-07-26 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 2.89%
H: 5.8%
C: 3.5%
trial therapeutics phase 2
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
Published: 2023-06-19 (Crawled : 00:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K
|
|
| O: -4.44%
H: 0.76%
C: -2.86%
program phase 2
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-05-09 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: -1.71%
ath434 australia global system trial therapeutics phase 2
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
Published: 2023-04-16 (Crawled : 00:00) - globenewswire.com
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 15.18%
H: 6.42%
C: 0.71%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.68%
H: 8.13%
C: 5.64%
candidate conference pneumococcal vaccine results study phase 2
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Published: 2023-03-30 (Crawled : 00:00) - globenewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.11%
H: 1.29%
C: 0.94%
lecanemab study phase 2
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Published: 2023-03-15 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 7.28%
H: 5.0%
C: -0.54%
ath434 system trial therapeutics phase 2
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Published: 2023-02-13 (Crawled : 00:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.02%
H: 1.32%
C: 0.99%
FUSN | $21.26 0.05% 0.05% 440K
|
Health Technology
|
| O: 5.81%
H: 0.0%
C: -0.55%
pharmaceuticals acquire program cancer prostate cancer phase 2
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
Published: 2022-12-21 (Crawled : 00:00) - biospace.com/
LXRX | $1.655 1.53% 1.51% 3M
|
Health Technology
|
| O: 0.52%
H: 3.63%
C: -1.55%
lx9211 topline results study phase 2
AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
Published: 2022-11-06 (Crawled : 00:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.07%
H: 6.5%
C: 2.87%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.33%
H: 3.48%
C: 3.31%
phase 2
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
IDYA | $37.1 -1.38% -1.4% 730K
|
Health Technology
|
| O: 10.27%
H: 20.39%
C: 18.53%
melanoma positive phase 2
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
Published: 2022-08-04 (Crawled : 00:00) - globenewswire.com
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: -0.6%
H: 10.87%
C: 9.11%
collaboration phase 2
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
Published: 2022-07-06 (Crawled : 00:00) - biospace.com/
CALA | $0.04 150.0% 5.3K
|
Health Technology
|
| O: 1.95%
H: 3.45%
C: -0.38%
trial cancer phase 2
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
Published: 2022-07-06 (Crawled : 00:00) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: 0.86%
H: 5.13%
C: 5.13%
advm-022 trial phase 2
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
Published: 2022-07-06 (Crawled : 00:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K
|
Health Technology
|
| O: -0.98%
H: 4.23%
C: 0.98%
dm199 trial therapeutics phase 2 clinical hold
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
Published: 2022-07-06 (Crawled : 00:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 0.23%
H: 6.74%
C: -0.57%
ata188 study phase 2
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy
Published: 2022-06-22 (Crawled : 00:00) - alteritytherapeutics.com
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 0.43%
H: 9.84%
C: 4.79%
ath434 trial therapeutics authorization phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.